

## PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1  
Stylesheet Version v1.2

Assignment ID: PATI252775

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT
<b>NATURE OF CONVEYANCE:</b>	ASSIGNMENT

**CONVEYING PARTY DATA**

Name	Execution Date
LivaNova Inc.	04/22/2024
LivaNova USA Inc.	04/22/2024

**RECEIVING PARTY DATA**

<b>Company Name:</b>	DiLorenzo Biomedical, LLC
<b>Street Address:</b>	P.O. Box 1626
<b>City:</b>	Loma Linda
<b>State/Country:</b>	CALIFORNIA
<b>Postal Code:</b>	92354

**PROPERTY NUMBERS Total: 33**

Property Type	Number
Patent Number:	6366813
Patent Number:	6819956
Patent Number:	7209787
Patent Number:	7242984
Patent Number:	7324851
Patent Number:	7277758
Patent Number:	7231254
Patent Number:	7403820
Patent Number:	7747325
Patent Number:	8762065
Patent Number:	9042988
Patent Number:	9375573
Patent Number:	9415222
Patent Number:	8396557
Patent Number:	7930035
Patent Number:	7853329
Patent Number:	7623928
Patent Number:	9421373
Patent Number:	9320900

PATENT

Property Type	Number
Patent Number:	9113801
Patent Number:	8781597
Patent Number:	8725243
Patent Number:	8868172
Patent Number:	7676263
Patent Number:	8370287
Patent Number:	8121972
Patent Number:	7840507
Patent Number:	7747551
Patent Number:	D627476
Patent Number:	8295934
Patent Number:	7974696
Patent Number:	9345880
Patent Number:	7599736

**CORRESPONDENCE DATA**

**Fax Number:** 9176335568

*Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.*

**Phone:** 2122471639

**Email:** michael.lewis@listonabramson.com

**Correspondent Name:** Mord Michael Lewis

**Address Line 1:** 405 Lexington Ave.

**Address Line 2:** 46th Floor

**Address Line 4:** New York, NEW YORK 10174

<b>ATTORNEY DOCKET NUMBER:</b>	DLZ
<b>NAME OF SUBMITTER:</b>	Mord Lewis
<b>SIGNATURE:</b>	Mord Lewis
<b>DATE SIGNED:</b>	05/23/2024

**Total Attachments: 5**

source=DiLorenzo-LivaNova Assignment#page1.tif  
source=DiLorenzo-LivaNova Assignment#page2.tif  
source=DiLorenzo-LivaNova Assignment#page3.tif  
source=DiLorenzo-LivaNova Assignment#page4.tif  
source=DiLorenzo-LivaNova Assignment#page5.tif

**EXHIBIT C**

**ASSIGNMENT**

Effective as of 04/22/2024 (“Effective Date”), for good and valuable consideration, the receipt and sufficiency whereof is hereby acknowledged by LivaNova Inc. and LivaNova USA Inc, (collectively, “Assignor”), Assignor hereby transfers, assigns, bargains, sells, and conveys unto DiLorenzo Biomedical, LLC (“Assignee”), Assignor’s entire right, title, and interest in and to those patents, patent applications, and related intellectual property rights, know-how, prototypes, and materials in the field of neural modulation, which were invented and/or developed in whole or in part by Assignee’s founder, Dr. Daniel J. DiLorenzo and/or the prior company he founded, NeuroVista Corporation, including the patents, patent applications, other intellectual property rights and items identified in Schedule A hereto (including Schedule A1 and Schedule A2), together with all patents that eventuate from applications included in the foregoing, and continuing, reissued, and reexamined applications and patents thereon, and any extensions thereof, worldwide, and all rights to sue and recover damages for past, present, and future infringement of any of said rights (collectively, the “IPRs”).

The representations, warranties, and covenants of Assignor set forth in that certain Agreement between Assignor and Assignee dated as of 04/22/2024, to the extent applicable by their terms with respect to the IPRs transferred by this assignment, are incorporated herein.

The assignment pursuant of rights hereto shall be binding upon and inure to the benefit of Assignor and Assignee (respectively), and their respective successors, assigns, and legal representatives.

**IN WITNESS WHEREOF**, Assignor has executed this Instrument of Assignment as of the Effective Date.

**LIVANOVA INC**

DocuSigned by:  
Signature:   
E591AE4CA8614E6...

Name: Alex Shvartsburg

Title: Chief Financial Officer

Date Signed: 2024-04-22 | 19:49 BST

**LIVANOVA USA INC**

DocuSigned by:  
Signature:   
E591AE4CA8614E6...

Name: Alex Shvartsburg

Title: Chief Financial Officer

Date Signed: 2024-04-22 | 19:49 BST

SCHEDULE A1  
SCHEDULE OF PATENTS

Category	Filing Date	SN	Patent #	Title	Inventor	Portfolio	Exp Date	Note
PDSTM - Provisional	6/25/1999	09/340,326		6,386,813 Apparatus and method for closed-loop intracranial stimulation for optimal control of neurological disease			6/25/2019	
	11/11/2001	10/008,576		6,819,956 Optimal method and apparatus for neural modulation for the treatment of neurological disease, particularly			6/25/2019	
	11/20/2003	10/718,248		7,209,787 Apparatus and method for closed-loop intracranial stimulation for optimal control of neurological disease			12/28/2019	adjusted expiration
	1/6/2004	10/753,205		7,242,984 Apparatus and method for closed-loop intracranial stimulation for optimal control of neurological disease			6/25/2020	adjusted expiration
	6/11/2004	10/858,899		7,324,851 Closed-loop Feedback-Driven Neuromodulation			1/31/2021	adjusted expiration
	4/5/2004	10/818,333		7,237,758 Methods and systems for predicting future symptomatology in a patient suffering from a neurological or psych			5/1/2021	adjusted expiration
	7/12/2004	10/889,844		7,231,254 Closed-loop Feedback-Driven Neuromodulation			11/28/2019	adjusted expiration
PDSTM - Utility US & PCT (portfolio from parent 813 patent)								
	5/25/2005	11/138,621		7,403,820 Closed-loop Feedback-driven Neuromodulation			2/9/2021	adjusted expiration
	9/28/2005	11/239,653		7,747,325 Systems And Methods For Monitoring A Patient's Neurological Disease State			3/31/2022	adjusted expiration
	6/22/2005	11/159,842		8,762,065 Closed-loop Feedback-driven Neuromodulation			12/28/2021	adjusted expiration
	11/17/2005	11/282,317		9,042,988 Closed-loop Vagus Nerve Stimulation			12/6/2019	adjusted expiration
	9/23/2005	11/234,873		9,375,573 Systems And Methods For Monitoring A Patient's Neurological Disease State			6/11/2021	adjusted expiration
	7/21/2008	12/177,060		9,415,222 Monitoring An Epilepsy Disease State With A Supervisory Module			10/7/2021	adjusted expiration
	4/4/2012	13,439,531		8,396,557 Extracranial Monitoring Of Brain Activity			6/25/2019	adjusted expiration
	5/2/2007	11/743,611		7,930,035 Providing Output Indicative Of Subject's Disease State			8/8/2021	adjusted expiration
	12/29/2006	11/647,900		7,853,329 Monitoring Efficacy Of Neural Modulation Therapy			10/1/2021	adjusted expiration
	5/2/2007	11/743,607		7,623,928 Controlling A Subject's Susceptibility To A Seizure			7/13/2019	adjusted expiration
	11/15/2006	11/600,527		9,421,373 Apparatus And Method For Closed-loop Intracranial Stimulation For Optimal Control Of Neurological Disease			10/11/2022	adjusted expiration
	12/29/2006	11/647,700		9,320,900 Methods And Systems For Determining Subject-specific Parameters For A Neuromodulation Therapy			5/13/2023	adjusted expiration
	12/29/2006	11/647,785		9,113,801 Methods And Systems For Continuous EEG Monitoring			6/23/2023	adjusted expiration
	5/5/2010	12/774,550		8,781,597 Systems For Monitoring A Patient's Neurological Disease State			2/23/2022	adjusted expiration
NeuroVista IP (with DLD as inventor)								
	12/28/2005	11/321,898		8,725,243 Methods And Systems For Recommending An Appropriate Pharmacological Treatment To A Patient For Ma	DJD & KWL		2/21/2030	adjusted expiration
	12/28/2005	11/321,897		8,868,172 Methods And Systems For Recommending An Appropriate Action To A Patient For Managing Epilepsy And	DJD & KWL		5/2/2028	adjusted expiration
	6/21/2007	11/766,760		7,676,263 Minimally Invasive System For Selecting Patient-specific Therapy Parameters	*JFH, KWL, JM		6/21/2027	anticipated expiration
NeuroVista IP (without DLD as inventor)								
	2/13/2012	13,572,468		8,370,287 Classification Of Patient Conditions Using Known And Artificial Classes	DS		1/29/2027	anticipated expiration
	10/14/2010	12,905,028		8,121,972 Reduction Of Classification Error Rates And Monitoring System Using An Artificial Class	DS		2/28/2027	anticipated expiration
	4/8/2010	12/756,953		7,840,507 Reduction Of Classification Error Rates And Monitoring System Using An Artificial Class	DS		2/28/2027	anticipated expiration
	2/26/2007	11/679,135		7,747,551 Reduction Of Classification Error Rates And Monitoring System Using An Artificial Class	DS		9/1/2028	anticipated expiration
	8/29/2007	D/284,040		D627476 Medical Patient Advisory Device	SG, MB, PDW, KWL, JFH		11/16/2024	anticipated expiration
	11/14/2006	11/599,179		8,295,934 Systems And Methods Of Reducing Artifact In Neurological Stimulation Systems	KWL		3/23/2027	adjusted expiration
Dilorenzo Biomedical LLC & Daniel John Dilorenzo owned IP (NOT assigned or licensed to NeuroBionics/BioNeuroics/NeuroVista or to Livanova)								
	7/23/2005	11/187,315		7,974,686 Closed-loop Autonomic Neuromodulation For Optimal Control Of Neurological And Metabolic Disease	DJD		6/27/2020	adjusted expiration
	1/17/2006	11/333,979		9,345,980 Closed-loop Feedback-driven Sympathetic Neuromodulation For Affect Control	DJD		3/6/2026	adjusted expiration
	7/19/2002	10/198,871		7,599,736 Method and Apparatus for the Neuromodulation and Physiologic Modulation for the Treatment of Metabolic	DJD		6/14/2023	adjusted expiration
Additional Patents and Applications								

\*: DLD contends he invented the minimally invasive subgaleal electrode design and procedure, discussed at BioNeuroics/NeuroVista, and had returned to residency when that patent was filed, so this may have been an inadvertent omission in the 263 patent

**SCHEDULE A2**

**Related Assets:**

**NeuroVista Data including but not limited to:**

**EEG Data**

**iEEG data**

**ECoG Data**

**Patient Data**

**Algorithm Test Data**

**NeuroVista Algorithm**

**Software code (including but not limited to:**

**Features, Feature Extractors, Classifiers (including but not limited to**

**Filtering layer parameters, 288 candidate features,**

**best 16 features for each pilot study patient,**

**Classifier design for each patient)**

**Source Code**

**Executable Code**

**Documentation**

**Validation Processes, Code, Data, and Results**

**Regulatory Approval and Quality related Processes, Code, Data, and**

**Results**

**NeuroVista Resources:**

**Computers, including but not limited to parallel processor computer,**

**operating system, software, hardware, documentation thereof, and**

**other related components**

**Preclinical data (including dog studies)**

**Clinical data (including but not limited to EEG data, ECOG Data, Pilot study data)**

**Pilot study data including but not limited to specific features and algorithm Properties and results for each patient**

**NeuroVista Hardware**

**Implanted devices (including but not limited to electrodes, electronic hardware, connecting cables, and other components)**

**Non-Implanted devices (including but not limited to patient module, physician programmer, data telemetry system)**

**Circuit diagrams**

**Customized chips and designs (including but not limited to ASICs, etc)**

**Software including but not limited to Firmware**

**NeuroVista Intellectual Property**

**Any logos, copyrights, trademarks, artwork, or other intellectual property or other related URL**